Did you or do you take any of these Rx's? You may still be eligible for some $$

This is still in litigation as I send this email -- John (May 26, 2006)

Press Release: Average Wholesale Price (AWP) Drug Litigation

Case Charging Nation’s Largest Drug Companies of Defrauding Consumers Moves Closer to Trial; Patients receiving physician-administered drugs urged to join suit

August 18, 2005

BOSTON - In a case charging the nation's leading drug companies with defrauding consumers and inflating the cost of prescriptions, U.S. District Court Judge Patti B. Saris has ruled she will grant the case national class-action status once attorneys for the plaintiffs make technical changes to the complaint.

The complaint was originally filed in 2002 by Seattle attorney Steve W. Berman, managing partner of Hagens Berman Sobol Shapiro, and alleges that drug manufacturers including AstraZeneca (NYSE:AZN), Bristol-Myers Squibb (NYSE:BMY) and GlaxoSmithKline (NYSE:GSK), routinely inflate the Average Wholesale Price (AWP) they report to trade publications as part of a scheme to defraud consumers. The Average Wholesale Price is the average cost of a drug on the wholesale market.

According to Judge Saris' class certification order, issued on August 16, 2005, the redefined class will include all persons who received physician-administered drugs manufactured by the drug companies in question.

Steve Berman said that the judge's order was made with the expectation that the suit against the defendants will move to trial. "Once technical changes are made to the complaint, Judge Saris ruled she will certify the class and that charges against the defendants will move forward."

The complaint focuses on a range of often-expensive drugs administered in a clinical setting. These medications are used in the treatment of many types of cancer and other serious illnesses. The new proposed class will include thousands of patients who received such treatments.

Attorneys said that it will be important to demonstrate the large number of individuals included in the class. As the case moves forward, attorneys are urging all people who received certain physician-administered drugs to add their name to a growing list of potential plaintiffs.

"Once we prove that thousands, even millions of innocent people have been defrauded and forced to pay inflated prices for their medications, the drug companies will be forced to give an account," Berman said. "That's why it is essential that individuals who have received these drugs stand up and be counted."

The prescription drugs mentioned in the complaint include:

Albuterol

Alkeran

Amikin

Amphotericin B

Blenoxane

Coumadin

Cytoxan

Diprivan

Etopophos

Floxin

Fungizone

Haldol

Imitrex

Integrilin

Intron-A

Kytril

Lanoxin

Levaquin

Myleran

Navelbine

Paraplatin

Procrit

Proventil

Pulmicort

Remicade

Retrovir

Risperdal

Rubex

Taxol

Temodar

Tequin IV

Ventolin

Vepesid

Zantac

Zofran

Zoladex

Zovirax

All persons who have received treatment with any of the above drugs will be considered a part of the class and may be eligible for monetary restitution.

Potential class members can join the suit by visiting www.hbsslaw.com/awp_info or by contacting Hagens Berman Sobol Shapiro at info@hbsslaw.com or (206) 443-9357.

###

HAGENS BERMAN SOBOL SHAPIRO LLP Attorneys at Law
206-623-7292 www.hbsslaw.com Media Contact: Mark Firmani 206-443-9357 mark@firmani.com